Welcome to our dedicated page for Roche Hldg news (Ticker: RHHBY), a resource for investors and traders seeking the latest updates and insights on Roche Hldg stock.
Roche Holding AG (RHHBY) is a global pioneer in biotechnology and diagnostics, driving innovations in personalized healthcare through groundbreaking pharmaceuticals and advanced diagnostic solutions. This dedicated news hub provides investors and industry professionals with timely updates on corporate developments, research breakthroughs, and strategic initiatives shaping modern medicine.
Access authoritative information on Roche's financial performance, regulatory milestones, and therapeutic advancements. Our curated news collection includes:
• Earnings reports and investor communications
• FDA/EMA regulatory updates
• Clinical trial results and R&D partnerships
• Diagnostic technology launches
• Strategic acquisitions and collaborations
Bookmark this page for comprehensive tracking of Roche's progress in oncology, immunology, and molecular diagnostics. Stay informed about developments impacting one of healthcare's most influential innovators through verified updates from primary sources.
Roche (RHHBY) has published phase III CENTERSTONE trial results for Xofluza (baloxavir marboxil) in the New England Journal of Medicine, demonstrating significant reduction in influenza virus transmission. The trial met its primary endpoint, showing a 32% reduction in the odds of virus transmission from infected individuals to untreated household members with a single oral dose.
While the key secondary endpoint of reducing symptomatic transmission showed clinically meaningful reduction, it did not reach statistical significance. The drug demonstrated a favorable safety profile with no new safety concerns identified.
The findings have been submitted to both the FDA and EMA for review. This breakthrough is particularly significant as approximately one-third of all influenza transmission occurs within households, with seasonal influenza affecting an estimated one billion people worldwide annually, causing millions of hospitalizations and up to 650,000 deaths globally.
Roche (RHHBY) reported strong Q1 2025 performance with Group sales growing 6% at constant exchange rates (CER) to CHF 15.4 billion. The Pharmaceuticals Division saw an 8% increase to CHF 11.9 billion, driven by newer medicines like Phesgo, Vabysmo, Xolair, and Hemlibra. The Diagnostics Division remained stable at CHF 3.5 billion.
Key regional performance showed US sales up 6%, Europe up 5%, Japan up 3%, and International markets up 18%. The company announced plans to invest USD 50 billion in US pharmaceuticals and diagnostics over five years, creating over 12,000 new jobs.
Notable developments include US approvals for Evrysdi tablet and Susvimo, EU approval for Columvi, and a collaboration with Zealand Pharma for weight loss treatments. Roche confirmed its 2025 outlook, expecting mid-single-digit sales growth and high-single-digit core earnings per share growth.
Roche (RHHBY) has received CE Mark approval for its innovative Chest Pain Triage algorithm, developed in collaboration with Universitätsklinikum Heidelberg. The algorithm, part of the navify® Algorithm Suite, aims to enhance the detection of Acute Coronary Syndrome (ACS) in emergency departments.
The technology leverages high-sensitivity cardiac troponin testing and European Society of Cardiology (ESC) guidelines to help differentiate between cardiac and non-cardiac chest pain. According to Roche Diagnostics CEO Matt Sause, the algorithm can reduce Emergency Department visit times by over three hours through an early rule-out pathway.
The algorithm provides Rule-In, Rule-Out, or Observe recommendations and automatically selects the proper ESC pathway based on blood sample timing. Currently available in Europe, the Middle East, and Asia, with future US availability planned, the system integrates with existing emergency department workflows through Electronic Health Records and Lab Information Systems.
Roche (RHHBY) has announced a major USD 50 billion investment in the United States over the next five years. The investment plan includes new R&D sites, expanded manufacturing facilities across Indiana, Pennsylvania, Massachusetts, and California, with an additional site location pending announcement.
The expansion will create over 12,000 new jobs, including 1,000 positions at Roche and 6,500 construction jobs. Key projects include: a gene therapy manufacturing facility in Pennsylvania, a 900,000 square foot manufacturing centre for weight loss medicines, a continuous glucose monitoring facility in Indiana, and a new AI-focused R&D centre in Massachusetts for cardiovascular research.
Building upon its existing presence of 25,000 employees across 24 sites in eight US states, Roche aims to strengthen its manufacturing and distribution capabilities. The company projects that once the new facilities are operational, its US medicine exports will exceed imports.
Roche (RHHBY) has received European Commission approval for Columvi in combination with gemcitabine and oxaliplatin (GemOx) for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplant.
The approval is based on the Phase III STARGLO study results, which showed that the Columvi combination demonstrated a 41% reduction in death risk compared to MabThera/Rituxan plus chemotherapy. The study revealed a median overall survival of 25.5 months for the Columvi combination versus 12.9 months for R-GemOx, with more than twice as many patients experiencing complete response (58.5% vs 25.3%).
This marks Columvi as the first bispecific antibody regimen available in Europe for DLBCL patients whose cancer has returned or didn't respond to initial treatment. The treatment offers an 'off-the-shelf' option with fixed duration, allowing immediate availability and a defined treatment endpoint.
Roche (RHHBY) has presented new data at AD/PD 2025 Conference showcasing advancements in Alzheimer's treatment and diagnostics. The company's trontinemab demonstrated promising Phase Ib/IIa results, showing rapid and deep amyloid plaque reduction in 81% of participants receiving 3.6 mg/kg dose after 28 weeks. The drug maintained a favorable safety profile with ARIA-E observed in less than 5% of participants.
The company plans to initiate a Phase III programme for trontinemab later this year. Additionally, Roche's Elecsys® pTau181 plasma test showed potential in accurately ruling out amyloid pathology in a study of 604 participants. This blood test is expected to be available in Europe by late 2025.
In Parkinson's disease research, the Phase IIb PADOVA study of prasinezumab, while missing its primary endpoint, showed possible benefits in early-stage patients, particularly those treated with levodopa.
Genentech and Roche presented significant advancements in Alzheimer's treatment and diagnostics at AD/PD 2025. The Phase Ib/IIa Brainshuttle AD study of trontinemab showed promising results, with 81% of participants in the 3.6 mg/kg dose group experiencing amyloid plaque reduction below threshold after 28 weeks. The drug demonstrated a favorable safety profile with ARIA-E observed in less than 5% of participants.
The company's Elecsys pTau181 plasma test showed potential in accurately ruling out amyloid pathology in a study of 604 participants. This minimally invasive blood test is expected to be available in Europe by late 2025. Additionally, Phase III trials for trontinemab will commence later this year.
In Parkinson's research, the Phase IIb PADOVA study of prasinezumab, while missing its primary endpoint, showed possible benefits in early-stage Parkinson's disease, particularly in levodopa-treated patients.
Roche (RHHBY) announced that its Phase III MUSETTE trial, testing a higher dose of OCREVUS® (ocrelizumab) against the current 600 mg dose in relapsing multiple sclerosis (RMS), did not meet its primary endpoint of showing additional benefit in slowing disability progression over 120 weeks of treatment.
The study revealed that the current 600 mg dose demonstrated optimal efficacy, with disability progression rates remaining low and consistent with previous pivotal studies. Notably, OCREVUS showed the lowest annualized relapse rate ever observed in a Phase III RMS study, with relapses occurring approximately once every 16 years.
OCREVUS maintains its position as the most prescribed disease-modifying therapy in the United States, with over 400,000 patients treated globally. Roche is expanding treatment accessibility through a new subcutaneous formulation and is developing a high-concentration formulation for convenient on-body device delivery.
Genentech announced that its Phase III MUSETTE trial, testing a higher dose of Ocrevus (ocrelizumab) against the standard 600 mg dose in relapsing multiple sclerosis (RMS), did not meet its primary endpoint of showing additional benefit in slowing disability progression.
The study revealed that disability progression rates remained low and consistent with previous pivotal studies. The standard 600 mg dose demonstrated strong efficacy with the lowest annualized relapse rate (ARR) observed in any Phase III RMS study, with relapses occurring approximately once every 16 years.
Ocrevus, the first B-cell therapy approved for RMS and PPMS, has become the most prescribed disease-modifying therapy in the United States, treating over 400,000 patients globally. The company is developing new delivery methods, including Ocrevus Zunovo™ and a high-concentration formulation for on-body device delivery.
Quest Diagnostics (NYSE: DGX) has launched a new FDA-cleared HPV self-collection solution for cervical cancer screening. The service allows patients to collect their own specimens in healthcare settings and will be available at Quest's 2,000 patient service centers starting next month.
The solution utilizes Roche's FDA-cleared HPV self-collection technology, approved for use with their cobas® HPV test in May 2024. This initiative follows Quest's successful launch of self-collection services for STIs in October 2024.
The self-collection option comes at no extra charge and aims to address the declining screening rates, with 4.4 million fewer American women receiving screenings in 2021 compared to 2019. The service is not FDA approved for at-home collection and is not intended to replace regular pelvic examinations.
